Prevalence of Lower and Upper Incisor Periodontal Phenotypes and Risk Indicators.
1 other identifier
observational
245
1 country
1
Brief Summary
The determination of the periodontal phenotype is an essential part of the periodontal diagnostic process, which must guide not only treatment but also prognosis (Kim et al. 2020). This determination is based on the clinical assessment of 3 individual variables: gingival height/thickness and alveolar bone cortical thickness. Although these anatomical characteristics are genetically determined, they are also influenced by numerous acquired, endogenous or exogenous factors that can act at a general and/or local level. The periodontal phenotype is therefore specific to an individual and its 3 components vary over time according to the dental sectors and sites of each individual. For example, the morphology of this phenotype varies according to whether the gingiva is thick or thin, high or reduced, and the bone cortex is thick or thin, with all possible combinations. Clinicians need to know the distribution of these different types of phenotypes, particularly in the aesthetic areas they are concerned with, in order to better identify the most fragile ones in the face of the multiple daily stresses to which the periodontium may be subjected: muscular force, dental plaque, oral hygiene manoeuvres, parafunctionality, dental procedures.... However, studies on the prevalence of the periodontal phenotype are limited and mainly concern Asian, Indian and American populations, with very few studies on European populations. Main objective: To assess the prevalence of periodontal phenotypes in the upper and lower incisors of French subjects, according to tooth type and at the individual level. Secondary objective: Identification of potential risk indicators in relation to the type of periodontal phenotype."
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 13, 2025
CompletedFirst Posted
Study publicly available on registry
May 21, 2025
CompletedStudy Start
First participant enrolled
July 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
May 21, 2025
May 1, 2025
1 year
May 13, 2025
May 19, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Prevalence of gingival phenotypes (gingival thickness )
Assessment of gingival thickness
At the inclusion
Prevalence of gingival phenotypes (keratinised tissue height)
Evaluation of keratinised tissue height of the lower and upper incisors with UNC-15 peridontal probe (mm) and clinical photography.
At the inclusion
Prevalence of gingival phenotypes (Photography)
Description of the gingiva
At the inclusion
Secondary Outcomes (2)
Associated risk indicators for thin gingival phenotype ( Clinical description)
At the inclusion
Associated risk indicators for thin gingival phenotype ( orthodontic and facial characteristics )
At the inclusion
Interventions
Assessment of gingival thickness (Kan et al 2015) and keratinised tissue height of the incisors with UNC-15 peridontal probe (Hu-Freidy, USA) and clinical photography.
Eligibility Criteria
Dental students at the university hospitals of Nice and Nancy (France)
You may qualify if:
- Age (18 years old or older),
- Dental student on the university hospitals of Nice and Nancy.
- Social security affiliate.
- Systemically healthy.
- Healthy and intact periodontium.
- Informed consent.
You may not qualify if:
- Pregnancy.
- Under any regular medical treatment.
- Active periodontal disease.
- Enduring orthodontic treatment.
- Periodontal surgery in the mandibulary anterior region.
- Non consent patient.
- Patient under judgment trials.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU NICE
Nice, Alpes Maritimes, 06000, France
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 13, 2025
First Posted
May 21, 2025
Study Start
July 1, 2025
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
May 21, 2025
Record last verified: 2025-05